Psilocybin for End-of-Life Anxiety: What the Research Shows
Among all the therapeutic applications of psilocybin, the treatment of end-of-life anxiety in cancer patients has the most replicated, most consistent, and most striking clinical results. Two research teams — at NYU Langone and Johns Hopkins — conducted nearly simultaneous trials in patients with life-threatening cancer diagnoses, and both found results that few pharmaceutical treatments have matched.
The Johns Hopkins and NYU Trials
Design: Both trials enrolled adults with life-threatening cancer diagnoses and significant anxiety or depression. Both used a randomized crossover design comparing high-dose psilocybin to a control (very low-dose psilocybin at Hopkins; active placebo niacin at NYU). Both provided facilitated sessions with preparation and integration therapy.
Hopkins results (Griffiths et al., 2016):
- 80% of participants showed clinically significant decreases in depression and anxiety at 6 months
- 83% showed increases in life satisfaction and quality of life
- Over 70% rated the experience as one of the five most meaningful of their lives
- Effects were sustained at the 6-month follow-up with no significant diminishment
NYU results (Ross et al., 2016):
- 83% of participants in the psilocybin condition showed clinically significant reduction in anxiety and depression
- 60–80% remained in the reduced-symptom category at 6.5-month follow-up
- Strong effects on spiritual wellbeing and acceptance of death
Both studies were published simultaneously in the Journal of Psychopharmacology in 2016, representing a landmark moment in psychedelic medicine.
Why Psilocybin Works for This Population
The death anxiety problem: When facing a terminal diagnosis, anxiety often involves a specific existential dimension — fear of the process of dying, fear of non-existence, grief about leaving loved ones, unresolved relational and meaning questions. Conventional anxiolytics (benzodiazepines, SSRIs) treat the anxiety symptom without addressing its existential content. Psilocybin appears to address the existential dimension directly.
The mystical experience and death acceptance: Participants in end-of-life trials frequently report mystical experiences involving a profound sense that consciousness extends beyond the individual self — experiences of connection, unity, and the irrelevance of personal extinction from a wider perspective. These are not delusions; they do not persist as fixed beliefs. But the felt encounter with a wider reality appears to transform the relationship to death in lasting ways.
Non-ordinary states and the review of life: Psilocybin sessions in this context often produce intensive, facilitated life review — processing unresolved relationships, recontextualizing life events, accessing and expressing things that felt unspeakable. This psychological work, combined with the neurobiological effects, produces outcomes that exceed conventional psychotherapy.
5-Year Follow-Up Data
A 2020 follow-up study of the Hopkins cohort at 4.5 years found that the improvements in anxiety, depression, and quality of life persisted. Most participants continued to rate the experience as one of the most personally meaningful of their lives. Multiple participants described the psilocybin session as having transformed their experience of dying — not eliminating fear, but changing its quality and their relationship to it.
Access in 2026
Clinical trials: Both Hopkins and NYU continue to conduct psilocybin research with seriously ill populations. ClinicalTrials.gov has current recruiting status.
Oregon service centers: Oregon service centers can provide services to any adult 21+ with a qualifying intention. Facilitators with oncology/palliative care backgrounds exist in the licensed workforce. Sessions are expensive and not insurance-covered.
Compassionate use: The FDA's Expanded Access pathway theoretically allows psilocybin for terminally ill patients outside of clinical trials, though this remains rarely utilized as of 2026.
Resources
- Hopkins CPCR end-of-life research: hopkinspsychedelic.org
- ClinicalTrials.gov: search "psilocybin + cancer anxiety" for recruiting trials
- Oregon Psilocybin Services: oregon.gov/oha/ph/psilocybin for licensed service centers